To provide long term capital appreciation and income.
Name | % Net Assets |
---|---|
Aviva Inv Absolute TAA Fund | 5.0% |
BG Group | 3.0% |
GlaxoSmithKline | 2.6% |
European Investment Bank 4.75% 2012 | 1.9% |
Vodafone Group | 1.5% |
Astrazeneca | 1.4% |
HSBC Holdings PLC (UK Reg) | 1.4% |
KFW Int Finance 5.625% 7/12/2009 | 1.3% |
2¼% Treasury Gilt 2014 | 1.0% |
US Treasury 1.75% 31/03/2014 | 1.0% |
Key | % Net Assets |
---|---|
![]() |
5.0% |
![]() |
3.0% |
![]() |
2.6% |
![]() |
1.9% |
![]() |
87.5% |
Date | 14-Feb-2025 |
---|---|
NAV | 211.38p |
Currency | GBP |
Change | -0.63p |
% | -0.30% |
YTD change | 4.82p |
YTD % | 2.33% |
Fund Inception | 19/02/2001 |
---|---|
Fund Manager | Peter Michaelis |
TER | 0.84 (31-Jan-2013) |
Minimum Investment | |
---|---|
Initial | £500000 |
Additional | n/a |
Savings | £50 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.75% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.11 |
You are here: research